Best of the 5th Annual Advanced Practice Provider IBD Immersion: An IBD-U Initiative

This continuing pharmacy education activity is provided by

Educational Partner:

This activity is supported by educational grants from AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc.

RELEASE DATE:

January 31, 2022

EXPIRATION DATE:

January 30, 2023

Activity Description

Inflammatory bowel disease (IBD) is a chronic relapsing condition. The main subtypes of IBD—Crohn’s disease and ulcerative colitis—are characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. They are difficult to accurately diagnose and manage, and treatment options can consist of both medical and surgical approaches. Advanced practice nurses, physician assistants, and pharmacists play integral roles in the care and management of patients with IBD, providing assessments, diagnosis, treatment/care planning, implementation, and evaluation. They also play a key role in supporting and educating patients and their caregivers. It is thus crucial that advanced practice clinicians possess the latest information on IBD treatments and management. During “Best of the 5th Annual Advanced Practice Provider IBD Immersion: An IBD-U Initiative,” experts in the field provide current evidence and guidance regarding the pathophysiology and assessment of IBD, in addition to the most recent evidence in medical and surgical approaches for the treatment of IBD.

Target Audience

The intended audience for this activity is pharmacists and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objective(s)

Upon successful completion of this educational activity, participants should be better able to:

  • Apply the latest medical advances, including biological therapies, to the treatment of patients with IBD.
  • Summarize surgical procedures used for IBD and approaches to reduce complications.
  • Evaluate everyday challenges as well as practical interventions and solutions that may improve the overall outcome and quality of life in patients with IBD.
  • Assess the significance of a multidisciplinary approach in the optimal management of patients with IBD in both the medical and surgical settings.

Course Co-Chairs

Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL

Faculty

Mary Ayers, BSN-RN
Nurse Manager
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Janice C. Colwell, APRN, CWOCN, FAAN
Advanced Practice Nurse, Ostomy and Wound Care
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Emily A. Dobrez, BSN, MSN, FNP
Nurse Practitioner
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
Sarah O’Rourke, DNP, APRN, AGPCNP-BC
Nurse Practitioner
University of Chicago Medicine Digestive Diseases Center
Chicago, IL
Michele Rubin, MSN, APN, CNS, CGRN
IBD Clinical Nurse Specialist
Director, Advanced Practice Nursing
Associate Director
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL

Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Linda A. Giarraputo, PA-C
Jennifer Labas, APN, FNP-BC
Barbara A. Niedz, PhD, RN, CPHQ

Accreditation

acpeVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation Statements

This program is acceptable for 1.75 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-9999-22-001-H01-P, effective 1/31/2022. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days. This enduring material is approved for 1 year from the date of original release, January 31, 2022, to January 30, 2023.

How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the content, and complete the CE posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a CPE Statement of Credit.

Disclosures

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education (ACCME’s) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. 

Course Co-Chairs, Planners, and Faculty report the following RELEVANT relationship(s)

Mary Ayers, BSN-RN
No relevant financial relationships to disclose.

Russell D. Cohen, MD, FACG, AGAF
Consultant: AbbVie, Bristol-Myer Squibb/Celgene, Genentech, Gilead, Hoffman LaRoche, Janssen, Lilly, Pfizer, Takeda, UCB
Speaker Contracted by Ineligible Company: AbbVie, Takeda
Independent Research Contractor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb/Celgene, Genentech, Gilead, Hollister, MedImmune, Mesoblast, Osiris, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres, Takeda, UCB

Janice C. Colwell, APRN, CWOCN, FAAN
Speaker Contracted by Ineligible Company: Coloplast

Emily A. Dobrez, BSN, MSN, FNP
Advisor: Bristol-Myers Squibb

Sarah O’Rourke, DNP, APRN, AGPCNP-BC
No relevant financial relationships to disclose.

David T. Rubin, MD
Consultant: AbbVie, Allergan, AltruBio, Arena, Athos, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Connect Biopharma, Genentech/Roche, Gilead, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen, Lilly, Pfizer, Prometheus, Reistone, Takeda, Techlab
Independent Research Contractor: Takeda

Michele Rubin, MSN, APN, CNS, CGRN
No relevant financial relationships to disclose.

Planners/Reviewers report the following RELEVANT relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
No relevant financial relationships to disclose.

Jennifer Labas, APN, FNP-BC
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following RELEVANT relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com